Arch Point Investors Abb Vie Inc. Transaction History

Arch Point Investors

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$107.43 - $135.93 $247,303 - $312,910	-2,302 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$106.4 - $120.78 $244,932 - $278,035	2,302 New	2,302 $248,000
Q2 2021 Aug 13, 2021	SELL	$105.21 - $117.21 $1.28 Million - $1.42 Million	-12,125 Closed	0 $0
Q1 2021 May 13, 2021	SELL	$102.3 - $112.62 $7,161 - $7,883	-70 Reduced 0.57%	12,125 $1.31 Million
Q4 2020 Feb 12, 2021	BUY	$80.49 - $108.67 $82,904 - $111,930	1,030 Added 9.23%	12,195 $1.31 Million
Q3 2020 Nov 13, 2020	BUY	$85.91 - $100.83 $274,912 - $322,656	3,200 Added 40.18%	11,165 $978,000
Q2 2020 Jul 31, 2020	SELL	$73.37 - $98.18 $82,174 - $109,961	-1,120 Reduced 12.33%	7,965 $782,000
Q1 2020 May 13, 2020	BUY	$64.5 - $97.79 $15,480 - $23,469	240 Added 2.71%	9,085 $692,000
Q3 2019 Nov 13, 2019	BUY	$62.98 - $75.72 $142,334 - $171,127	2,260 Added 34.32%	8,845 $670,000
Q2 2019 Jul 26, 2019	BUY	$65.7 - $83.98 $52,231 - $66,764	795 Added 13.73%	6,585 $479,000
Q3 2018 Oct 24, 2018	BUY	$88.91 - $98.84 $127,585 - $141,835	1,435 Added 32.95%	5,790 $548,000
Q2 2018 Aug 14, 2018	SELL	$89.78 - $106.23 $48,032 - $56,833	-535 Reduced 10.94%	4,355 $403,000
Q1 2018 May 15, 2018	SELL	$92.01 - $123.21 $31,743 - $42,507	-345 Reduced 6.59%	4,890 $463,000
Q3 2017 Nov 14, 2017	BUY	$69.85 - $89.22 $365,664 - $467,066	5,235	5,235 $465,000

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Arch Point Investors, based on Form 13F filings with the SEC.

Stay updated on Arch Point Investors with notifications on news.